Original Article
Survey of immunoglobulin products for the treatment of antibody-mediated rejection after organ transplantation
2023 Volume 58 Issue 4 Pages 381-388
Details
2023 Volume 58 Issue 4 Pages 381-388
We retrospectively surveyed the status of IVIg use in treatment for antibody-mediated rejection (AMR) in Japan between 2001 and 2022 for kidney, liver, pancreas, pancreatic islet. heart, lung, and intestine transplantation.
One hundred eighty-eight clinical departments responded. Of these, 54 clinical departments used IVIg for AMR. In addition, IVIg was administered to 17 in the kidney, 61 in the liver, 11 in the heart, 48 in the lung, 4 in the pancreas, and 3 in intestine.
We report on treatment details and IVIg dosage.
